Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.

Prabakaran M, Kumar SR, Raj KV, Wu X, He F, Zhou J, Kwang J.

Antiviral Res. 2014 Sep;109:149-59. doi: 10.1016/j.antiviral.2014.06.017. Epub 2014 Jul 2.

PMID:
24997413
2.

Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Rajesh Kumar S, Syed Khader SM, Kiener TK, Szyporta M, Kwang J.

PLoS One. 2013 Jun 7;8(6):e63856. doi: 10.1371/journal.pone.0063856. Print 2013.

3.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

4.

Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.

Prabakaran M, Kolpe AB, He F, Kwang J.

Vaccine. 2013 Feb 27;31(10):1385-92. doi: 10.1016/j.vaccine.2013.01.003. Epub 2013 Jan 14.

PMID:
23328313
5.

Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.

Musthaq SK, Kumar SR, Szyporta M, Kwang J.

Antiviral Res. 2014 Sep;109:42-53. doi: 10.1016/j.antiviral.2014.06.002. Epub 2014 Jun 25.

PMID:
24973759
6.

Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.

Zhang L, Jia N, Li J, Han Y, Cao W, Wang S, Huang Z, Lu S.

Hum Vaccin Immunother. 2014;10(7):1949-58. doi: 10.4161/hv.28795.

7.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

8.

Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice.

Prabakaran M, Meng T, He F, Yunrui T, Qiang J, Lin RT, Kwang J.

Clin Vaccine Immunol. 2011 Sep;18(9):1582-5. doi: 10.1128/CVI.05114-11. Epub 2011 Jul 13.

9.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

10.

Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J.

J Virol. 2010 Apr;84(7):3201-9. doi: 10.1128/JVI.02175-09. Epub 2010 Jan 13.

11.

H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.

Rudenko L, Isakova-Sivak I, Donina S.

Vaccine. 2013 Oct 1;31(42):4702-5. doi: 10.1016/j.vaccine.2013.08.040. Epub 2013 Aug 26.

PMID:
23988294
12.

Amino Acid Substitutions Improve the Immunogenicity of H7N7HA Protein and Protect Mice against Lethal H7N7 Viral Challenge.

Kumar SR, Prabakaran M, Ashok Raj KV, He F, Kwang J.

PLoS One. 2015 Jun 1;10(6):e0128940. doi: 10.1371/journal.pone.0128940. eCollection 2015.

13.

Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.

Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C, Burroughs A, Sun X, Maines TR, Levine MZ, York IA.

J Virol. 2017 Sep 27;91(20). pii: e01202-17. doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.

14.

Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.

Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, Chang CC, Chan CH, Liu CC, Chen JR.

Vaccine. 2014 Jul 31;32(35):4485-94. doi: 10.1016/j.vaccine.2014.06.043. Epub 2014 Jun 21.

15.

Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.

Overton ET, Goepfert PA, Cunningham P, Carter WA, Horvath J, Young D, Strayer DR.

Vaccine. 2014 Sep 22;32(42):5490-5. doi: 10.1016/j.vaccine.2014.07.078. Epub 2014 Aug 13.

PMID:
25128802
16.

Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus.

Xu Q, Chen Z, Cheng X, Xu L, Jin H.

PLoS One. 2013 Oct 9;8(10):e76884. doi: 10.1371/journal.pone.0076884. eCollection 2013.

17.

Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection.

Li Z, Gabbard JD, Johnson S, Dlugolenski D, Phan S, Tompkins SM, He B.

PLoS One. 2015 Mar 24;10(3):e0120355. doi: 10.1371/journal.pone.0120355. eCollection 2015.

18.

Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine.

Carter DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, Isakova-Sivak I, Rudenko L, Ross TM.

Vaccine. 2015 Jan 1;33(1):108-16. doi: 10.1016/j.vaccine.2014.11.008. Epub 2014 Nov 18.

PMID:
25448100
19.

Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.

Kwon HI, Kim YI, Park SJ, Song MS, Kim EH, Kim SM, Si YJ, Lee IW, Song BM, Lee YJ, Yun SJ, Kim WJ, Choi YK.

J Virol. 2017 May 12;91(11). pii: e02259-16. doi: 10.1128/JVI.02259-16. Print 2017 Jun 1.

20.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811

Supplemental Content

Support Center